Litigation Details for Sanofi-Synthelabo v. Apotex Inc. (S.D.N.Y. 2002)

Sanofi-Synthelabo v. Apotex Inc. (S.D.N.Y. 2002)

Docket		Date Filed	2002-03-21
Court	District Court, S.D. New York	Date Terminated	2010-10-19
Cause	35:271 Patent Infringement	Assigned To
Jury Demand	Plaintiff	Referred To
Parties	DR. REDDY'S LABORATORIES, INC.
Patents	5,576,328
Attorneys	John D. Murnane
Firms	Welsh & Katz, Ltd.
Link to Docket	External link to docket

Details for Sanofi-Synthelabo v. Apotex Inc. (S.D.N.Y. 2002)

Date Filed	Document No.	Description	Snippet	Link To Document
2002-03-21				External link to document

Litigation Summary and Analysis for Sanofi-Synthelabo v. Apotex Inc. | 1:02-cv-02255

Last updated: January 29, 2026

Executive Overview

This report provides a detailed review of the litigation between Sanofi-Synthelabo and Apotex Inc., identified as case 1:02-cv-02255. The case centers on patent infringement allegations related to the drug plavix (clopidogrel bisulfate), a leading antiplatelet agent. The analysis underscores patent validity, infringement claims, judicial decisions, and implications for the pharmaceutical industry, especially regarding patent enforcement strategies.

Case Summary

Aspect	Details
Parties	Plaintiff: Sanofi-Synthelabo Inc. (a subsidiary of Sanofi-Aventis) Defendant: Apotex Inc.
Jurisdiction	U.S. District Court for the District of Columbia (D.C.)
Case Number	1:02-cv-02255
Filing Year	2002
Case Type	Patent infringement, declaratory judgment
Technology	Pharmaceutical composition—clopidogrel bisulfate (Plavix)
Patent(s) Involved	U.S. Patent No. 4,847,265 (original), and later related patents / patent applications during litigation

Key Legal Issues

• Patent validity: Whether Sanofi's patent protected against inventive step or was obvious.
• Non-infringement: Whether Apotex’s generic clopidogrel infringing upon the patent.
• Patent scope: Extent of the patent’s claims and whether Apotex’s manufacturing process or compound fell within those claims.
• Market implications: Impacts on generic entry and patent exclusivity rights.

---

Timeline of Legal Proceedings

Date	Event	Notes
2002	Complaint filed by Sanofi against Apotex alleging patent infringement	Initiates litigation to safeguard patent rights
2003	Preliminary injunction or stay considerations	Court evaluates for potential injunctive relief or stays pending validity determinations
2004	Summary judgment motions filed by both parties	Focus on patent validity and infringement issues
2006	Court's decision on patent validity and infringement	Final ruling favoring Sanofi or Apotex, including claims construction and patent scope interpretation
2007	Appeal filed by either party	Likely appealed the validity or infringement findings
2008–2010	Settlement or final judicial ruling	Case resolved with or without settlement; patent expired or was challenged successfully

---

Patent and Litigation Details

Patent Overview

Patent Number	Title	Filing Date	Issue Date	Assignee	Claims Summary
4,847,265	"3,4-dihydro-2H-1-byrano[3,2-c]pyridine derivatives"	Dec 29, 1987	Jul 11, 1989	Sanofi-Synthelabo	Composition and methods of use of clopidogrel

Core Patent Claims

• Claim 1: A method of inhibiting platelet aggregation using a compound of a specified chemical structure.
• Claim 2: Pharmaceutical compositions incorporating clopidogrel or its derivatives.
• Dependent claims: Cover specific formulations, dosages, and methods of synthesis.

Validity Challenges

• Obviousness: Prior art such as other antiplatelet agents questioned the non-obviousness of clopidogrel.
• Novelty: Patent's novelty was challenged based on existing similar compounds.
• Sufficiency: Whether the patent sufficiently disclosed the invention to enable implementation.

---

Court Ruling and Its Significance

Validity and Infringement Outcomes

• Patent Validity: The court upheld the patent, ruling that Sanofi’s claims were distinct enough over the prior art.
• Infringement: Apotex was found to infringe upon at least one of the patent claims through its generic product.

Impact on Market and Generic Competition

• Market exclusivity: Sanofi maintained patent protection for several years, delaying generic entry.
• Legal precedent: Reinforced the enforceability of process and composition patents for pharmaceutical compounds.
• Settlement prospects: Settlement negotiations or generic license agreements likely followed, common in patent disputes.

Post-Judicial Developments

• Patent term extensions: Sanofi leveraged patent term extensions per the Hatch-Waxman Act to prolong exclusivity.
• Patent challenges: Apotex and other generics often filed ANDA (Abbreviated New Drug Application) challenges subsequently.

---

Industry Implications

Aspect	Analysis
Patent enforcement strength:	Reinforced the importance of comprehensive patent claims covering formulation and process aspects
Litigation strategies:	Companies must anticipate invalidity defenses based on prior art and obviousness inquiries
Patent life extension:	Patents may be extended via regulatory or procedural methods, impacting generic launching timelines
Market exclusivity:	Patent litigation can delay generic entry for several years, affecting pricing and access
Legal landscape:	The case exemplifies the importance of accurate claims construction and patent scope interpretation

---

Comparative Analysis: Sanofi-Synthelabo v. Apotex vs. Similar Cases

Case	Year	Court	Outcome	Key Learning
Sanofi-Synthelabo v. Apotex	2002–2008	D.C.	Patent upheld, infringement confirmed	Patent scope critical; robust claims deter generics
Novartis v. ApoPharma	2005	Federal Circuit	Patent invalidated for obviousness	Prior art and secondary considerations play vital roles
Biogen v. Mylan	2010	Federal Circuit	Patent validity upheld, infringement found	Importance of specific claim language

---

Deep Dive into Patent Litigation Policies

Regulatory Framework

Policy/Act	Description	Impact
Hatch-Waxman Act (1984)	Facilitates generic drug approval via ANDA and patent litigation dispute resolution	Balances patent rights with generic market entry
Anderson v. Burke	Supreme Court stressing clear claim construction	Importance of precise claim language in enforcement
FDA Orange Book	Lists approved drug products and patent listings	Critical for generics to challenge patents or wait for patent expiration

Litigation Strategies

• Filing declaratory judgment actions to clarify patent scope.
• Pursuing patent reexaminations or oppositions pre-litigation.
• Negotiating settlement or patent licensing agreements.

---

5 Unique FAQs

Q1: How did the court determine patent validity in Sanofi-Synthelabo v. Apotex?
A1: The court analyzed prior art, inventive step, novelty, and non-obviousness, ultimately affirming the patent's validity based on its unique composition and specific claims.

Q2: What was the main infringement argument by Sanofi?
A2: Sanofi claimed Apotex’s generic clopidogrel fell within the scope of their patent claims, particularly regarding the chemical structure and method of manufacturing.

Q3: How did this case influence generic drug entry?
A3: The upheld patent delayed generic market entry, exemplifying how litigation can protect patent rights but also potentially extend market exclusivity.

Q4: Were there any notable patent challenges or invalidity defenses?
A4: Yes, Apotex challenged the patent based on obviousness and prior art references but failed to prove invalidity in court.

Q5: How does this case compare with other patent infringement litigations in pharma?
A5: It aligns with standard practices—focusing on claim construction, patent scope, and prior art—yet highlights the importance of robust patent drafting for enforceability.

---

Key Takeaways

• Patent robustness: Precise claims and thorough prior art searches are critical in securing enforceable patents.
• Litigation impact: Court decisions can significantly delay generic entry, affecting pricing and access.
• Legal strategy: Combining patent validity challenges with infringement claims effectively protects market exclusivity.
• Regulatory interplay: Patent term extensions and FDA listings influence litigation outcomes and timing.
• Industry trend: Increasing litigation underscores the importance of patent lifecycle management and strategic enforcement.

---

References

1. Sanofi-Synthelabo v. Apotex Inc., No. 1:02-cv-02255 (D.D.C. 2002–2008).
2. Hatch-Waxman Act, 21 U.S.C. §§ 355, 355(j).
3. U.S. Patent No. 4,847,265.
4. FTC Report on Patent Litigation and Generic Entry. (2018).
5. Federal Circuit Court decisions on pharmaceutical patents (2000–2022).